One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   In-Vitro Diagnostics (IVD) Global Market

体外診断(IVD)グローバル市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] In-Vitro Diagnostics (IVD) Global Market - Forecast To 2028


Product Code : IQ4IHC00116242
Survey : IQ4I
Publish On : December, 2021
Category : Healthcare and Pharmaceuticals
Study Area : North America (U.S. and Others), Europe (Germany, France, U.K. and Others), Asia-Pacific (Japan, China, India, and Others), Rest of World (Brazil, Rest of Latin America, Middle East & Others)
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4950 / Question Form
5 User USD6750 / Question Form
Enterprise User USD9000 / Question Form
ABBOTT LABORATORIES
BIOMEREIEUX
DANAHER CORPORATION
DEXCOM INC.
F. HOFFMANN LA ROCHE
HOLOGIC, INC.
QUIDEL CORPORATION
SIEMENS HEALTHINEERS
SYSMEX
THERMO FISHER SCIENTIFIC
LIST OF COMPANIES MENTIONED IN REPORT

[Report Description]

In-vitro diagnostic (IVD) are tests where reagents, instruments, and systems determine the state of health, to cure, mitigate, treat, or prevent disease. These tests can be performed on a variety of instruments such as small, handheld tests to complex laboratory instruments allowing doctors to diagnose patients effectively and decide to provide appropriate treatments.
According to IQ4I analysis, the In vitro diagnostic global market is expected to grow at low single digit CAGR from 2021 to 2028 to reach $96,485.2 million by 2028. The factors such as the growing incidence of chronic and infectious diseases, increasing adoption of point-of-care testing, the emergence of Next-generation molecular diagnostics, minimally invasive and non-invasive in-vitro diagnostics, rising number of CLIA-waived tests are driving the growth of the IVD market. However, the rising number of product recalls, lack of skilled laboratory technicians in developing nations, inadequate reimbursements, and stringent regulatory framework is expected to hamper the market growth.
The in-vitro diagnostics global market is segmented based on products, technology, applications, sample source, end-users and geography. The products market is segmented into instruments, reagents and software & services, where, reagents commanded the largest share of the market in 2021 and is expected to grow at low single digit CAGR from 2021 to 2028.
The IVD global market based on technology is segmented into immunochemistry, clinical chemistry, molecular diagnostics, clinical microbiology, hematology, coagulation and hemostasis and others. Among these, the immunochemistry segment commanded the largest share in 2021 and the market is expected to grow at low single digit CAGR from 2021 to 2028. The immunochemistry market is further sub-segmented based on techniques into Enzyme-Linked Immunosorbent Assay (ELISA), Enzyme-Linked Immunospot (Elispot) Assay, Radioimmunoassay (RIA), Rapid Tests, Chemiluminescence Immunoassay (CLIA), Fluoro Immunoassay (FIA), and Others. Among these, ELISA commanded the largest share in 2021; the rapid test segment occupied a significant share of the techniques market in 2021. The clinical chemistry market is sub-segmented based on technique into basic metabolic profile, electrolyte panel, liver panel, lipid profile, renal profile, thyroid function panel and others, among which, the basic metabolic profile commanded the largest share of the market in 2021, the lipid profile segment is expected to grow at a high single digit CAGR from 2021 to 2028. The molecular diagnostics market is further sub-segmented into PCR, microfluidics & microarray, INAAT, in-situ hybridization, NGS and others. Among these, the PCR segment generated the largest revenue in 2021, Microfluidics & microarray segment is expected to grow at early teen CAGR from 2021 to 2028.
The IVD global market based on application is segmented into oncology, diabetes, infectious diseases, genetic testing, cardiology, autoimmune diseases, drug testing, nephrology, transplantation, Blood & related disorders, and others, among them, the infectious disease segment commanded the largest revenue in 2021, the transplantation segment is expected to grow at high double digit CAGR from 2021 to 2028. The oncology market is further sub-segmented based on cancer types into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer and others, among which, colorectal cancer commanded the largest share in 2021 and the market is expected to grow at a high single digit CAGR from 2021 to 2028. The oncology market based on cancer care is further sub-segmented into diagnosis, early screening, companion diagnostics, prognosis and recurrence monitoring, where, diagnosis commanded the largest share of the market in 2021, the companion diagnostics segment is expected to grow at high single digit CAGR from 2021 to 2028. The infectious disease market is further sub-segment into bacterial, viral infection, fungal and others among which the viral infection commanded the largest share of the market in 2021. The bacterial infection global market is further segmented based on infection agent into Treponema pallidum, Gardnerella, Staphylococcus aureus, Clostridium difficile, Streptococcus (A&B), Methicillin-resistant Staphylococcus aureus (MRSA), Chlamydia trachomatis (CT) & Neisseria gonorrhea (NG) and tuberculosis (TB) and others. Among these, Staphylococcus aureus commanded the largest revenue in 2021. The MRSA segment is expected to grow at low single digit CAGR from 2021 to 2028. The Viral infection global market is segmented based on the type of infection into HIV-1, influenza, dengue, Hepatitis B, Hepatitis C, Human papillomavirus (HPV), herpes simplex virus (HSC), zika virus, and COVID & others. Among these, the COVID & others segment contributed the largest share of the market in 2021, HIV-1 segment is expected to grow at a double digit CAGR from 2021 to 2028. The Fungal infection global market based on the type of infection is segmented into Candida, Aspergillus, and others. Among these, Candida commanded the largest revenue in 2021. The other infections segment is further sub-segmented into malaria, trichomonas vaginalis and others, among this, Trichomonas vaginalis commanded the largest share in 2021, and malaria is expected to grow at low single digit CAGR from 2021 to 2028.
The IVD global market based on sample source is segmented into blood, urine, mucus and others, among which blood commanded the largest share of the market in 2021, and is expected to grow at mid single digit CAGR from 2021 to 2028. The blood-based tests provide accurate results when compare to other sources, and, they are suitable sample sources for early diagnosis before the occurrence of symptoms.
The In-vitro diagnostics end-user market is segmented into diagnostic laboratories, hospitals, academics and research centers, homecare and other end-users. The hospitals' segment accounted for the largest revenue in 2021 and is estimated to grow at low single digit CAGR from 2021 to 2028 due to the availability of advanced and novel technologies for the diagnosis and also the availability of skilled professionals with more capital investments.
Geographical-wise, the North America region commanded the largest revenue in 2021 owing to the high demand for early detection, treatment and prevention tests with advanced technology. However, the Asia-Pacific region is expected to grow at mid single digit CAGR from 2021 to 2028 with increasing awareness for the highly precise, rapid and advanced tests for a better outcome.
The in-vitro diagnostics global market is competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the IVD global market include Abbott Laboratories, Inc. (U.S.), F.Hoffmann-La Roche AG (Switzerland), Siemens Healthineers(Germany), Biomerieux SA (France), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), Sysmex (Japan), Dexcom (U.S), Hologic (U.S), Quidel (U.S) Qiagen N.V. (the Netherlands) and Thermo Fisher Scientific, Inc. (U.S.).
The report provides an in-depth market analysis of the above-mentioned segments across the following regions:
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)


1 EXECUTIVE SUMMARY 34
2 INTRODUCTION 41
2.1 KEY TAKE AWAYS 41
2.2 SCOPE OF THE REPORT 42
2.3 REPORT DESCRIPTION 42
2.4 MARKETS COVERED 45
2.5 STAKEHOLDERS 50
2.6 RESEARCH METHODOLOGY 50
2.6.1 MARKET SIZE ESTIMATION 52
2.6.2 MARKET BREAKDOWN & DATA TRIANGULATION 55
2.6.3 SECONDARY SOURCES 56
2.6.4 PRIMARY SOURCES 57
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES 57
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES 58
2.6.7 ASSUMPTIONS 59
3 MARKET ANALYSIS 61
3.1 INTRODUCTION 61
3.2 MARKET SEGMENTATION 62
3.3 FACTORS INFLUENCING MARKET 66
3.3.1 DRIVERS AND OPPORTUNITIES 66
3.3.1.1 Growing incidence of chronic and infectious diseases 66
3.3.1.2 Increase in demand for IVD tests due to COVID-19 pandemic 68
3.3.1.3 Increasing adoption of point-of-care testing 68
3.3.1.4 The emergence of next-generation molecular diagnostics 70
3.3.1.5 Growing awareness of companion diagnostics and personalized medicine 70
3.3.1.6 The emergence of minimally invasive and non-invasive diagnostics 72
3.3.1.7 Rising number of CLIA-waived IVD tests 73
3.3.2 RESTRAINTS & THREATS 74
3.3.2.1 Rising incidence of product recalls 74
3.3.2.2 Lack of skilled laboratory technicians in developing nations 75
3.3.2.3 Inadequate reimbursement 75
3.3.2.4 Stringent regulatory framework 77
3.4 PORTER’S FIVE FORCE ANALYSIS 78
3.4.1 THREAT OF NEW ENTRANTS 79
3.4.2 THREAT OF SUBSTITUTES 80
3.4.3 COMPETITIVE RIVALRY 81
3.4.4 BARGAINING POWER OF SUPPLIERS 82
3.4.5 BARGAINING POWER OF BUYERS 82
3.5 REGULATORY AFFAIRS 83
3.5.1 U.S.A 83
3.5.2 EUROPE 86
3.5.3 CHINA 87
3.5.4 INDIA 88
3.5.5 JAPAN 89
3.5.6 AUSTRALIA 90
3.5.7 SOUTH KOREA 91
3.6 TECHNOLOGICAL ADVANCEMENTS 92
3.7 FUNDING SCENARIO 97
3.8 MERGERS & ACQUISITIONS 110
3.9 SUPPLY CHAIN ANALYSIS 114
3.10 IMPACT OF COVID-19 117
3.11 CLINICAL TRIALS 118
3.11.1 CFDNA CLINICALTRIALS 118
3.11.2 CIRCULATING TUMOR CELLS (CTC) 119
3.11.3 COMPANION DIAGNOSTICS 120
3.11.4 IMMUNOASSAYS 121
3.11.5 LIPID PROFILE 122
3.11.6 MICROARRAY 123
3.11.7 GENETIC DISEASES 124
3.12 MARKET SHARE ANALYSIS BY IN-VITRO DIAGNOSTICS MAJOR PLAYERS 125
3.12.1 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS 125
3.12.2 IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS 130
3.12.3 CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS 134
3.12.4 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS 137
3.12.5 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS 141
3.12.6 HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS BY MAJOR PLAYERS 144
3.12.7 COAGULATION AND HEMOSTASIS MARKET SHARE ANALYSIS BY MAJOR PLAYERS 147
4 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY PRODUCT 150
4.1 INTRODUCTION 150
4.2 INSTRUMENTS 152
4.3 REAGENTS 156
4.4 SOFTWARE AND SERVICES 160
5 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY TECHNOLOGY 163
5.1 INTRODUCTION 163
5.2 IMMUNOCHEMISTRY 166
5.2.1 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 170
5.2.2 ENZYME-LINKED IMMUNOSPOT (ELISPOT) ASSAY 174
5.2.3 RADIOIMMUNOASSAY (RIA) 176
5.2.4 RAPID TESTS 179
5.2.5 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) 183
5.2.6 FLUORESCENCE IMMUNOASSAYS (FIA) 185
5.2.7 OTHER IMMUNOASSAYS 188
5.3 CLINICAL CHEMISTRY 191
5.3.1 BASIC METABOLIC PROFILE 197
5.3.2 ELECTROLYTE PANEL 200
5.3.3 LIVER PANEL 203
5.3.4 LIPID PANEL 206
5.3.5 RENAL PANEL 209
5.3.6 THYROID FUNCTION PANEL 212
5.3.7 OTHERS (CLINICAL CHEMISTRY TESTS) 214
5.4 MOLECULAR DIAGNOSTICS (MDX) 216
5.4.1 PCR (POLYMERASE CHAIN REACTION) 223
5.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) 227
5.4.3 MICROFLUIDICS & MICROARRAY 230
5.4.4 IN SITU HYBRIDIZATION (ISH) 234
5.4.5 NEXT-GENERATION SEQUENCING (NGS) 238
5.4.6 OTHER MDX TECHNOLOGIES 241
5.5 CLINICAL MICROBIOLOGY 244
5.6 HEMATOLOGY 247
5.7 COAGULATION AND HEMOSTASIS 250
5.8 OTHERS 254
6 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY APPLICATION 257
6.1 INTRODUCTION 257
6.2 ONCOLOGY 261
6.2.1 CANCER TYPES 265
6.2.1.1 Introduction 265
6.2.1.2 Lung Cancer 265
6.2.1.3 Breast Cancer 268
6.2.1.4 Colorectal Cancer 270
6.2.1.5 Prostate Cancer 272
6.2.1.6 Melanoma 274
6.2.1.7 Ovarian Cancer 276
6.2.1.8 Others 278
6.2.2 CANCER CARE 281
6.2.2.1 Introduction 281
6.2.2.2 Diagnosis 285
6.2.2.3 Early Screening 287
6.2.2.4 Companion Diagnostics 290
6.2.2.5 Prognosis Monitoring 292
6.2.2.6 Recurrence Monitoring 293
6.3 DIABETES 295
6.4 INFECTIOUS DISEASES 298
6.4.1 BACTERIAL INFECTION 302
6.4.1.1 Treponema pallidum 306
6.4.1.2 Gardnerella vaginalis 310
6.4.1.3 Staphylococcus aureus 312
6.4.1.4 Clostridium difficile 315
6.4.1.5 Streptococcus (A & B) 318
6.4.1.6 Methicillin-Resistant Staphylococcus Aureus (MRSA) 320
6.4.1.7 Chlamydia trachomatis (CT) And Neisseria gonorrhoeae (NG) 323
6.4.1.8 Tuberculosis (TB) 326
6.4.1.9 Other Bacterial Infection 329
6.4.2 VIRAL INFECTION 333
6.4.2.1 HIV-1 338
6.4.2.2 Influenza 342
6.4.2.3 Dengue 345
6.4.2.4 Hepatitis B 348
6.4.2.5 Hepatitis C 351
6.4.2.6 Human Papilloma Virus (HPV) 353
6.4.2.7 Herpes Simplex Virus (HSV) 355
6.4.2.8 Zika Virus 359
6.4.2.9 COVID and Other Viral Infection 361
6.4.3 FUNGAL INFECTION 366
6.4.3.1 Candida 369
6.4.3.2 Aspergillus 371
6.4.3.3 Other Fungal Infection 372
6.4.4 OTHER INFECTION 374
6.4.4.1 Malaria 376
6.4.4.2 Trichomonas vaginalis 378
6.4.4.3 Other Infections 380
6.5 GENETIC TESTING 383
6.6 CARDIOLOGY DISEASES 392
6.7 AUTOIMMUNE DISEASES 395
6.8 DRUG TESTING 398
6.9 NEPHROLOGY 402
6.10 TRANSPLANTATION 404
6.11 BLOOD AND RELATED DISORDERS 413
6.12 OTHER DISEASES 416
7 IN-VITRO DIAGNOSTICS MARKET, BY SAMPLE TYPE 419
7.1 INTRODUCTION 419
7.2 BLOOD 421
7.3 MUCUS 425
7.4 URINE 426
7.5 OTHERS 430
8 IN-VITRO DIAGNOSTICS GLOBAL MARKET, BY END-USER 436
8.1 INTRODUCTION 436
8.2 DIAGNOSTIC LABORATORIES 439
8.3 HOSPITALS 443
8.4 ACADEMIC & RESEARCH CENTRES 446
8.5 HOME CARE 449
8.6 OTHER END-USERS 452
9 REGIONAL MARKET ANALYSIS 455
9.1 INTRODUCTION 455
9.2 NORTH AMERICA 459
9.2.1 U.S. 493
9.2.2 REST OF NORTH AMERICA 500
9.3 EUROPE 505
9.3.1 GERMANY 539
9.3.2 U.K. 544
9.3.3 FRANCE 548
9.3.4 REST OF E.U. 552
9.4 ASIA PACIFIC 557
9.4.1 JAPAN 590
9.4.2 CHINA 595
9.4.3 INDIA 600
9.4.4 REST OF APAC 606
9.5 REST OF THE WORLD 611
9.5.1 BRAZIL 644
9.5.2 REST OF LATIN AMERICA 650
9.5.3 MIDDLE EAST AND OTHERS 654
10 COMPANY DEVELOPMENTS 659
10.1 INTRODUCTION 659
10.1.1 REGULATORY APPROVAL AS A MAJOR GROWTH STRATEGY OF IN-VITRO DIAGNOSTICS MARKET PLAYERS 660
10.2 APPROVAL 660
10.3 NEW PRODUCT LAUNCH 670
10.4 AGREEMENTS PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES 677
10.5 MERGERS AND ACQUISITIONS 681
10.6 BUSINESS EXPANSION 684
11 COMPANY PROFILES 685
11.1 ABBOTT LABORATORIES 685
11.1.1 OVERVIEW 685
11.1.2 FINANCIALS 686
11.1.3 PRODUCT PORTFOLIO 690
11.1.4 KEY DEVELOPMENTS 691
11.1.5 BUSINESS STRATEGY 692
11.1.6 SWOT ANALYSIS 693
11.2 BIOMERIEUX 694
11.2.1 OVERVIEW 694
11.2.2 FINANCIALS 695
11.2.3 PRODUCT PORTFOLIO 698
11.2.4 KEY DEVELOPMENTS 701
11.2.5 BUSINESS STRATEGY 704
11.2.6 SWOT ANALYSIS 705
11.3 DANAHER CORPORATION 706
11.3.1 OVERVIEW 706
11.3.2 FINANCIALS 707
11.3.3 PRODUCT PORTFOLIO 709
11.3.4 KEY DEVELOPMENTS 721
11.3.5 BUSINESS STRATEGY 725
11.3.6 SWOT ANALYSIS 727
11.4 DEXCOM, INC. 728
11.4.1 OVERVIEW 728
11.4.2 FINANCIALS 729
11.4.3 PRODUCT PORTFOLIO 731
11.4.4 KEY DEVELOPMENTS 732
11.4.5 BUSINESS STRATEGY 733
11.4.6 SWOT ANALYSIS 734
11.5 F. HOFFMANN LA ROCHE 735
11.5.1 OVERVIEW 735
11.5.2 FINANCIALS 736
11.5.3 PRODUCT PORTFOLIO 740
11.5.4 KEY DEVELOPMENTS 742
11.5.5 BUSINESS STRATEGY 746
11.5.6 SWOT ANALYSIS 747
11.6 HOLOGIC, INC. 748
11.6.1 OVERVIEW 748
11.6.2 FINANCIALS 749
11.6.3 PRODUCT PORTFOLIO 752
11.6.4 KEY DEVELOPMENTS 754
11.6.5 BUSINESS STRATEGY 755
11.6.6 SWOT ANALYSIS 756
11.7 QUIDEL CORPORATION 757
11.7.1 OVERVIEW 757
11.7.2 FINANCIALS 758
11.7.3 PRODUCT PORTFOLIO 760
11.7.4 KEY DEVELOPMENTS 761
11.7.5 BUSINESS STRATEGY 764
11.7.6 SWOT ANALYSIS 765
11.8 SIEMENS HEALTHINEERS 766
11.8.1 OVERVIEW 766
11.8.2 FINANCIALS 767
11.8.3 PRODUCT PORTFOLIO 770
11.8.4 KEY DEVELOPMENTS 773
11.8.5 BUSINESS STRATEGY 775
11.8.6 SWOT ANALYSIS 776
11.9 SYSMEX 777
11.9.1 OVERVIEW 777
11.9.2 FINANCIALS 778
11.9.3 PRODUCT PORTFOLIO 780
11.9.4 KEY DEVELOPMENTS 781
11.9.5 BUSINESS STRATEGY 781
11.9.6 SWOT ANALYSIS 782
11.10 THERMO FISHER SCIENTIFIC 783
11.10.1 OVERVIEW 783
11.10.2 FINANCIALS 784
11.10.3 PRODUCT PORTFOLIO 787
11.10.4 KEY DEVELOPMENTS 788
11.10.5 BUSINESS STRATEGY 791
11.10.6 SWOT ANALYSIS 792

LIST OF TABLES
TABLE 1 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 39
TABLE 2 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY PRODUCT
(2020-2028) ($MN) 151
TABLE 3 IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET REVENUE,
BY REGION (2020-2028) ($MN) 155
TABLE 4 IN-VITRO DIAGNOSTICS REAGENTS GLOBAL MARKET REVENUE,
BY REGION, (2020-2028) ($MN) 159
TABLE 5 IN-VITRO DIAGNOSTICS SOFTWARE AND SERVICES GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 162
TABLE 6 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNOLOGY (2020-2028) ($MN) 164
TABLE 7 IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 167
TABLE 8 IMMUNOCHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE
(2020-2028) ($MN) 169
TABLE 9 ELISA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 172
TABLE 10 ELISPOT GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 175
TABLE 11 RADIOIMMUNOASSAY (RIA) GLOBAL MARKET REVENUE, BY REGION
(2020-2028) ($MN) 178
TABLE 12 RAPID TESTS GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 181
TABLE 13 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA) GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 184
TABLE 14 FLUORESCENCE IMMUNOASSAYS (FIA) GLOBAL MARKET REVENUE,
BY REGION, (2020-2028) ($MN) 187
TABLE 15 OTHER IMMUNOASSAYS GLOBAL MARKET REVENUE, BY REGION
(2020-2028) ($MN) 190
TABLE 16 CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY REGION
(2020-2028) ($MN) 194
TABLE 17 CLINICAL CHEMISTRY GLOBAL MARKET REVENUE, BY TECHNIQUE
(2020-2028) ($MN) 196
TABLE 18 BASIC METABOLIC PROFILE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 199
TABLE 19 ELECTROLYTE PANEL GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 202
TABLE 20 LIVER PANEL GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 205
TABLE 21 LIPID PANEL GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 208
TABLE 22 RENAL PROFILE GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 211
TABLE 23 THYROID FUNCTION PANEL GLOBAL MARKET REVENUE, BY REGION
(2020-2028) ($MN) 213
TABLE 24 OTHER GLOBAL MARKET REVENUE, BY REGION (2020-2028) ($MN) 215
TABLE 25 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 219
TABLE 26 MOLECULAR DIAGNOSTICS GLOBAL MARKET REVENUE, BY TECHNIQUE (2020-2028) ($MN) 221
TABLE 27 PCR GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 226
TABLE 28 INAAT GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 229
TABLE 29 MICROFLUIDICS & MICROARRAY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 233
TABLE 30 IN SITU HYBRIDIZATION GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 237
TABLE 31 NGS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 240
TABLE 32 OTHER MDX TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 242
TABLE 33 CLINICAL MICROBIOLOGY GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 246
TABLE 34 HEMATOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 249
TABLE 35 COAGULATION AND HEMOSTASIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 252
TABLE 36 OTHER TECHNOLOGIES GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 255
TABLE 37 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY APPLICATION (2020-2028) ($MN) 259
TABLE 38 ONCOLOGY GLOBAL MARKET REVENUE, BY CANCER TYPE,
(2020-2028) ($MN) 262
TABLE 39 ONCOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 264
TABLE 40 LUNG CANCER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 267
TABLE 41 BREAST CANCER GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 269
TABLE 42 COLORECTAL CANCER GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 271
TABLE 43 PROSTATE CANCER GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 274
TABLE 44 MELANOMA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 276
TABLE 45 OVARIAN CANCER GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 278
TABLE 46 OTHER CANCERS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 280
TABLE 47 CANCER DIAGNOSTICS GLOBAL MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN) 283
TABLE 48 DIAGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 286
TABLE 49 EARLY SCREENING GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 288
TABLE 50 COMPANION DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 291
TABLE 51 PROGNOSIS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 293
TABLE 52 RECURRENCE MONITORING GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 294
TABLE 53 DIABETES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 297
TABLE 54 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN) 299
TABLE 55 INFECTIOUS DISEASES GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 301
TABLE 56 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY INFECTION
(2020-2028) ($MN) 304
TABLE 57 BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 306
TABLE 58 TREPONEMA PALLIDUM GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 308
TABLE 59 GARDNERELLA VAGINALIS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 311
TABLE 60 S. AUREUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 313
TABLE 61 CLOSTRIDIUM DIFFICILE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 316
TABLE 62 STREPTOCOCCUS (A & B) GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 319
TABLE 63 MRSA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 322
TABLE 64 CT/NG GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 325
TABLE 65 TUBERCULOSIS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 328
TABLE 66 OTHER BACTERIAL INFECTION GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 332
TABLE 67 VIRAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION (2020-2028) ($MN) 335
TABLE 68 VIRAL INFECTION GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 337
TABLE 69 HIV-1 GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 340
TABLE 70 INFLUENZA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 344
TABLE 71 DENGUE GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 346
TABLE 72 HEPATITIS B GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 349
TABLE 73 HEPATITIS C GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 352
TABLE 74 HPV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 354
TABLE 75 HSV GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 357
TABLE 76 ZIKA VIRUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 360
TABLE 77 COVID AND OTHER VIRUSES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 364
TABLE 78 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 367
TABLE 79 FUNGAL INFECTION GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 369
TABLE 80 CANDIDA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 370
TABLE 81 ASPERGILLUS GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 372
TABLE 82 OTHER FUNGAL GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 373
TABLE 83 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY TYPE,
(2020-2028) ($MN) 374
TABLE 84 MALARIA GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 377
TABLE 85 TRICHOMONAS VAGINALIS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 379
TABLE 86 OTHER INFECTIONS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 382
TABLE 87 GENETIC TESTING GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 384
TABLE 88 CARDIOLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 394
TABLE 89 AUTOIMMUNE DISEASES GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 397
TABLE 90 DRUG TESTING GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 400
TABLE 91 NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 403
TABLE 92 TRANSPLANTATION GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 406
TABLE 93 BLOOD AND RELATED DISORDER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 415
TABLE 94 OTHER DISEASES GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 418
TABLE 95 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN) 420
TABLE 96 BLOOD SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 424
TABLE 97 MUCUS SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 426
TABLE 98 URINE SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 429
TABLE 99 OTHER SAMPLE SOURCE GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 434
TABLE 100 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY END-USERS, (2020-2028) ($MN) 437
TABLE 101 DIAGNOSTIC LABORATORIES GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 441
TABLE 102 HOSPITALS END-USER GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 445
TABLE 103 ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET REVENUE, BY REGION, (2020-2028) ($MN) 448
TABLE 104 HOME CARE END-USERS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 451
TABLE 105 OTHER END USERS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 454
TABLE 106 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION,
(2020-2028) ($MN) 456
TABLE 107 NORTH AMERICA IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN) 461
TABLE 108 NORTH AMERICA IVD MARKET REVENUE, BY TECHNOLOGY,
(2020-2028) ($MN) 463
TABLE 109 NORTH AMERICA IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN) 465
TABLE 110 NORTH AMERICA CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN) 467
TABLE 111 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET REVENUE,
BY TECHNIQUE, (2020-2028) ($MN) 469
TABLE 112 NORTH AMERICA IVD MARKET REVENUE, BY APPLICATION,
(2020-2028) ($MN) 471
TABLE 113 NORTH AMERICA ONCOLOGY MARKET REVENUE, BY CANCER TYPE,
(2020-2028) ($MN) 473
TABLE 114 NORTH AMERICA CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN) 475
TABLE 115 NORTH AMERICA INFECTIOUS DISEASES MARKET REVENUE,
BY APPLICATION, (2020-2028) ($MN) 477
TABLE 116 NORTH AMERICA BACTERIAL INFECTION MARKET REVENUE,
BY TYPE OF INFECTION, (2020-2028) ($MN) 479
TABLE 117 NORTH AMERICA VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 481
TABLE 118 NORTH AMERICA FUNGAL INFECTION MARKET REVENUE, BY INFECTION, (2020-2028) ($MN) 483
TABLE 119 NORTH AMERICA OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 485
TABLE 120 NORTH AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE,
(2020-2028) ($MN) 487
TABLE 121 NORTH AMERICA IVD MARKET REVENUE, BY END USERS,
(2020-2028) ($MN) 489
TABLE 122 NORTH AMERICA IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN) 491
TABLE 123 EUROPE IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN) 507
TABLE 124 EUROPE IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN) 509
TABLE 125 EUROPE IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 511
TABLE 126 EUROPE CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 513
TABLE 127 EUROPE MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN) 515
TABLE 128 EUROPE IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN) 517
TABLE 129 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER TYPE,
(2020-2028) ($MN) 519
TABLE 130 EUROPE ONCOLOGY MARKET REVENUE, BY CANCER CARE,
(2020-2028) ($MN) 521
TABLE 131 EUROPE INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN) 523
TABLE 132 EUROPE BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 525
TABLE 133 EUROPE VIRAL INFECTION MARKET REVENUE, BY INFECTION,
(2020-2028) ($MN) 527
TABLE 134 EUROPE FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 529
TABLE 135 EUROPE OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 531
TABLE 136 EUROPE IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN) 533
TABLE 137 EUROPE IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN) 535
TABLE 138 EUROPE IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN) 537
TABLE 139 APAC IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN) 559
TABLE 140 APAC IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN) 561
TABLE 141 APAC IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 563
TABLE 142 APAC CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 565
TABLE 143 APAC MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN) 567
TABLE 144 APAC IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN) 569
TABLE 145 APAC ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN) 571
TABLE 146 APAC ONCOLOGY MARKET REVENUE, BY CANCER CARE, (2020-2028) ($MN) 573
TABLE 147 APAC INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION,
(2020-2028) ($MN) 575
TABLE 148 APAC BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 577
TABLE 149 APAC VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION,
(2020-2028) ($MN) 579
TABLE 150 APAC FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 581
TABLE 151 APAC OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 583
TABLE 152 APAC IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN) 585
TABLE 153 APAC IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN) 587
TABLE 154 APAC IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN) 589
TABLE 155 ROW IVD MARKET REVENUE, BY PRODUCT, (2020-2028) ($MN) 613
TABLE 156 ROW IVD MARKET REVENUE, BY TECHNOLOGY, (2020-2028) ($MN) 615
TABLE 157 ROW IMMUNOCHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 617
TABLE 158 ROW CLINICAL CHEMISTRY MARKET REVENUE, BY TECHNIQUE,
(2020-2028) ($MN) 619
TABLE 159 ROW MOLECULAR DIAGNOSTICS MARKET REVENUE, BY TECHNIQUE, (2020-2028) ($MN) 621
TABLE 160 ROW IVD MARKET REVENUE, BY APPLICATION, (2020-2028) ($MN) 623
TABLE 161 ROW ONCOLOGY MARKET REVENUE, BY CANCER TYPE, (2020-2028) ($MN) 625
TABLE 162 ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE,
(2020-2028) ($MN) 627
TABLE 163 ROW INFECTIOUS DISEASES MARKET REVENUE, BY APPLICATION,
(2020-2028) ($MN) 629
TABLE 164 ROW BACTERIAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 631
TABLE 165 ROW VIRAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION,
(2020-2028) ($MN) 633
TABLE 166 ROW FUNGAL INFECTION MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 635
TABLE 167 ROW OTHER INFECTIONS MARKET REVENUE, BY TYPE OF INFECTION, (2020-2028) ($MN) 637
TABLE 168 ROW IVD MARKET REVENUE, BY SAMPLE SOURCE, (2020-2028) ($MN) 639
TABLE 169 ROW IVD MARKET REVENUE, BY END USERS, (2020-2028) ($MN) 641
TABLE 170 ROW IVD MARKET REVENUE, BY COUNTRY, (2020-2028) ($MN) 643
TABLE 171 APPROVALS (2020-2021) 661
TABLE 172 NEW PRODUCT LAUNCH (2020-2021) 670
TABLE 173 COLLABORATIONS (2020-2021) 678
TABLE 174 MERGERS AND ACQUISITIONS (2020-2021) 682
TABLE 175 BUSINESS EXPANSION (2020-2021) 684
TABLE 176 ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES,
(2019-2021) (Q2) ($MN) 686
TABLE 177 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT,
(2019-2021)(Q2) ($MN) 687
TABLE 178 ABBOTT LABORATORIES: DIAGNOSTICS, BY SUB-SEGMENT,
(2019-2021) (Q2) ($MN) 688
TABLE 179 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY,
(2019-2021) (Q2) ($MN) 689
TABLE 180 BIOMERIEUX: TOTAL REVENUE AND R&D EXPENSES,
(2019-2021) (Q2) ($MN) 695
TABLE 181 BIOMERIEUX: TOTAL REVENUE, BY SEGMENTS, (2019-2021)(Q2) ($MN) 696
TABLE 182 BIOMERIEUX: TOTAL REVENUE, BY SUB SEGMENTS,
(2019-2021)(Q2) ($MN) 697
TABLE 183 BIOMERIEUX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q2) ($MN) 698
TABLE 184 DANAHER CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2019-2021) (Q2) ($MN) 707
TABLE 185 DANAHER CORPORATION: TOTAL REVENUE, BY SEGMENT,
(2019-2021) (Q2) ($MN) 708
TABLE 186 DANAHER CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
(2019-2021) (Q2) ($MN) 709
TABLE 187 DEXCOM, INC: TOTAL REVENUE AND R&D EXPENSES
(2019-2021) (Q2) ($MN) 729
TABLE 188 DEXCOM, INC: TOTAL REVENUE, BY SEGMENT (2019-2021)(Q2) ($MN) 730
TABLE 189 DEXCOM, INC: TOTAL REVENUE, BY GEOGRAPHY (2019-2021) (Q2) ($MN) 731
TABLE 190 F. HOFFMANN LA ROCHE: TOTAL REVENUE AND R&D EXPENSES,
(2019-2021) (Q2) ($MN) 736
TABLE 191 F. HOFFMANN LA ROCHE: TOTAL REVENUE, BY SEGMENT,
(2019-2021) (Q2) ($MN) 737
TABLE 192 F. HOFFMANN LA ROCHE: DIAGNOSTICS, BY DIAGNOSTICS SUB-SEGMENT, (2019-2021) (Q2) ($MN) 738
TABLE 193 HOFFMANN LA ROCHE: DIAGNOSTICS DIVISION TOTAL REVENUE,
BY GEOGRAPHY, (2019-2021) (Q2) ($MN) 739
TABLE 194 HOLOGIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN) 749
TABLE 195 HOLOGIC: TOTAL REVENUE, BY SEGMENT, (2019-2021) (Q2) ($MN) 750
TABLE 196 HOLOGIC: DIAGNOSTICS, SUB SEGMENTS, (2019-2021) (Q2) ($MN) 751
TABLE 197 HOLOGIC: TOTAL REVENUE, BY GEOGRAPHY, (2020-2021) (Q2) ($MN) 752
TABLE 198 QUIDEL CORPORATION: TOTAL REVENUE AND R&D EXPENSES,
(2019-2021) (Q2) ($MN) 758
TABLE 199 QUIDEL CORPORATION: TOTAL REVENUE, BY SEGMENT,
(2019-2021) (Q2) ($MN) 759
TABLE 200 QUIDEL CORPORATION: TOTAL REVENUE, BY GEOGRAPHY,
(2019-2021) (Q2) ($MN) 760
TABLE 201 SIEMENS HEALTHINEERS: TOTAL REVENUE AND R&D EXPENSES,
(2019- 2021) (Q2) ($MN) 767
TABLE 202 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY SEGMENT,
(2019-2021) (Q2) ($MN) 768
TABLE 203 SIEMENS HEALTHINEERS: TOTAL REVENUE, BY GEOGRAPHY,
(2019-2021) (Q2) ($MN) 769
TABLE 204 SYSMEX: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q1) ($MN) 778
TABLE 205 SYSMEX: TOTAL REVENUE, BY GEOGRAPHY, (2019-2021) (Q1) ($MN) 779
TABLE 206 THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) (Q2) ($MN) 784
TABLE 207 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT,
(2019-2021) (Q2) ($MN) 785
TABLE 208 THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY,
(2019-2021) (Q2) ($MN) 786

LIST OF FIGURES
FIGURE 1 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION
(2020-2028) ($MN) 40
FIGURE 2 RESEARCH METHODOLOGY: IN-VITRO DIAGNOSTICS GLOBAL MARKET 52
FIGURE 3 IN-VITRO DIAGNOSTICS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH 53
FIGURE 4 IN-VITRO DIAGNOSTICS GLOBAL MARKET: FORECASTING MODEL 54
FIGURE 5 IN-VITRO DIAGNOSTICS GLOBAL MARKET: MARKET BREAKDOWN & DATA TRIANGULATION 55
FIGURE 6 IVD MARKET SEGMENTATION 63
FIGURE 7 IVD TECHNOLOGY MARKET SUB-SEGMENTS 64
FIGURE 8 IVD APPLICATION MARKET SUB-SEGMENTS 65
FIGURE 9 MARKET DYNAMICS 66
FIGURE 10 IN-VITRO DIAGNOSTICS GLOBAL MARKET: PORTER’S ANALYSIS 79
FIGURE 11 IN-VITRO DIAGNOSTICS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS 114
FIGURE 12 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%) 125
FIGURE 13 IMMUNOCHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%) 130
FIGURE 14 CLINICAL CHEMISTRY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%) 134
FIGURE 15 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%) 137
FIGURE 16 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 141
FIGURE 17 HEMATOLOGY GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2021 (%) 144
FIGURE 18 COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE ANALYSIS,
BY MAJOR PLAYERS, 2021 (%) 147
FIGURE 19 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY PRODUCT,
(2021 V/S 2028) (%) 152
FIGURE 20 IN-VITRO DIAGNOSTICS INSTRUMENTS GLOBAL MARKET SHARE,
BY REGION, (2021 V/S 2028) (%) 156
FIGURE 21 IN-VITRO DIAGNOSTICS REAGENTS MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 160
FIGURE 22 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNOLOGY,
(2021) CAGR (%) 165
FIGURE 23 IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 168
FIGURE 24 IMMUNOCHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 170
FIGURE 25 ELISA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 173
FIGURE 26 ELISPOT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 176
FIGURE 27 RIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 179
FIGURE 28 RAPID TESTS GLOBAL MARKET SHARE, BY REGION (2021 V/S 2028) (%) 182
FIGURE 29 CLIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 185
FIGURE 30 FIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 188
FIGURE 31 OTHER IMMUNOASSAYS GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 191
FIGURE 32 CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 195
FIGURE 33 CLINICAL CHEMISTRY GLOBAL MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 197
FIGURE 34 BASIC METABOLIC PROFILE GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 200
FIGURE 35 ELECTROLYTE PANEL GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 203
FIGURE 36 LIVER PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 206
FIGURE 37 LIPID PANEL GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 209
FIGURE 38 RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 212
FIGURE 39 RENAL PROFILE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 214
FIGURE 40 OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 216
FIGURE 41 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 220
FIGURE 42 MOLECULAR DIAGNOSTICS GLOBAL MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 222
FIGURE 43 PCR GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 227
FIGURE 44 INAAT GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 230
FIGURE 45 MICROFLUIDICS & MICROARRAY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 234
FIGURE 46 IN SITU HYBRIDIZATION GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 238
FIGURE 47 NGS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 241
FIGURE 48 OTHER MDX TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 243
FIGURE 49 CLINICAL MICROBIOLOGY GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 247
FIGURE 50 HEMATOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 250
FIGURE 51 COAGULATION AND HEMOSTASIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 253
FIGURE 52 OTHER TECHNOLOGIES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 256
FIGURE 53 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY APPLICATION,
(2021 V/S 2028) (%) 260
FIGURE 54 ONCOLOGY GLOBAL MARKET SHARE, BY CANCER TYPE,
(2021 V/S 2028)(%) 263
FIGURE 55 COLORECTAL CANCER GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 272
FIGURE 56 OTHERS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 281
FIGURE 57 CANCER DIAGNOSTICS GLOBAL MARKET SHARE, BY CANCER CARE,
(2021 V/S 2028) (%) 284
FIGURE 58 EARLY SCREENING GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 289
FIGURE 59 DIABETES GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 298
FIGURE 60 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY APPLICATION,
(2021 V/S 2028) (%) 300
FIGURE 61 INFECTIOUS DISEASES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 302
FIGURE 62 BACTERIAL INFECTION GLOBAL MARKET SHARE, BY INFECTION,
(2021) (%) (CAGR) 305
FIGURE 63 TREPONEMA PALLIDUM GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 309
FIGURE 64 S. AUREUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 314
FIGURE 65 CLOSTRIDIUM DIFFICILE GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 317
FIGURE 66 STREPTOCOCCUS (A & B) GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 320
FIGURE 67 MRSA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 323
FIGURE 68 CT/NG GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 326
FIGURE 69 TUBERCULOSIS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 329
FIGURE 70 OTHER BACTERIAL INFECTION GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 333
FIGURE 71 VIRAL INFECTIONS GLOBAL MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 336
FIGURE 72 VIRAL INFECTION GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 338
FIGURE 73 HIV-1 GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 341
FIGURE 74 INFLUENZA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 345
FIGURE 75 DENGUE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 347
FIGURE 76 HEPATITIS B GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 350
FIGURE 77 HPV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 355
FIGURE 78 HSV GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 358
FIGURE 79 ZIKA VIRUS GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 361
FIGURE 80 COVID AND OTHER VIRUSES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 365
FIGURE 81 FUNGAL INFECTION GLOBAL MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 368
FIGURE 82 OTHER INFECTIONS GLOBAL MARKET SHARE, BY TYPE,
(2021 V/S 2028) (%) 375
FIGURE 83 MALARIA GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 378
FIGURE 84 TRICHOMONAS VAGINALIS GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 380
FIGURE 85 OTHER INFECTIONS GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 383
FIGURE 86 GENETIC TESTING GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 385
FIGURE 87 CARDIOLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 395
FIGURE 88 AUTOIMMUNE DISEASES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 398
FIGURE 89 DRUG TESTING GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 401
FIGURE 90 NEPHROLOGY GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 404
FIGURE 91 TRANSPLANTATION GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 407
FIGURE 92 BLOOD AND RELATED DISORDER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 416
FIGURE 93 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%) 421
FIGURE 94 BLOOD SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 425
FIGURE 95 URINE SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 430
FIGURE 96 OTHER SAMPLE SOURCE GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 435
FIGURE 97 IN-VITRO DIAGNOSTICS GLOBAL MARKET SHARE, BY END-USERS,
(2021 V/S 2028) (%) 438
FIGURE 98 DIAGNOSTIC LABORATORIES GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 442
FIGURE 99 HOSPITALS END-USER GLOBAL MARKET SHARE, BY REGION,
(2021 V/S 2028) (%) 446
FIGURE 100 ACADEMICS AND RESEARCH CENTERS END-USER GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 449
FIGURE 101 HOME CARE GLOBAL MARKET SHARE, BY REGION, (2021 V/S 2028) (%) 452
FIGURE 102 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION
(2020-2028) ($MN) 457
FIGURE 103 IN-VITRO DIAGNOSTICS GLOBAL MARKET REVENUE, BY REGION AND COUNTRY, (2021) ($MN) 458
FIGURE 104 NORTH AMERICA IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%) 462
FIGURE 105 NORTH AMERICA IVD MARKET SHARE, BY TECHNOLOGY,
(2021 V/S 2028) (%) 464
FIGURE 106 NORTH AMERICA IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%) 466
FIGURE 107 NORTH AMERICA CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE, (2021 V/S 2028) (%) 468
FIGURE 108 NORTH AMERICA MOLECULAR DIAGNOSTICS MARKET SHARE,
BY TECHNIQUE, (2021 V/S 2028) (%) 470
FIGURE 109 NORTH AMERICA IVD MARKET SHARE, BY APPLICATION,
(2021 V/S 2028) (%) 472
FIGURE 110 NORTH AMERICA ONCOLOGY MARKET SHARE, BY CANCER TYPE,
(2021) (%) 474
FIGURE 111 NORTH AMERICA CANCER DIAGNOSTICS MARKET SHARE,
BY CANCER CARE, (2021 V/S 2028) (%) 476
FIGURE 112 NORTH AMERICA INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%) 478
FIGURE 113 NORTH AMERICA BACTERIAL INFECTION MARKET SHARE,
BY TYPE OF INFECTION, (2021 V/S 2028) (%) 480
FIGURE 114 NORTH AMERICA VIRAL INFECTION MARKET SHARE,
BY TYPE OF INFECTION, (2021 V/S 2028) (%) 482
FIGURE 115 NORTH AMERICA FUNGAL INFECTION MARKET SHARE,
BY TYPE OF INFECTION, (2021 V/S 2028) (%) 484
FIGURE 116 NORTH AMERICA OTHER INFECTIONS MARKET SHARE,
BY TYPE OF INFECTION, (2021 V/S 2028) (%) 486
FIGURE 117 NORTH AMERICA IVD MARKET SHARE, BY SAMPLE SOURCE,
(2021 V/S 2028) (%) 488
FIGURE 118 NORTH AMERICA IVD MARKET SHARE, BY END-USERS,
(2021 V/S 2028) (%) 490
FIGURE 119 NORTH AMERICA IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%) 492
FIGURE 120 U.S. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 497
FIGURE 121 U.S. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 498
FIGURE 122 U.S. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 499
FIGURE 123 REST OF N.A. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 502
FIGURE 124 REST OF N.A. IVD MARKET REVENUE, BY APPLICATION
(2021 V/S 2028) ($MN) 503
FIGURE 125 REST OF N.A. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 504
FIGURE 126 EUROPE IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%) 508
FIGURE 127 EUROPE IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%) 510
FIGURE 128 EUROPE IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 512
FIGURE 129 EUROPE CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 514
FIGURE 130 EUROPE MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 516
FIGURE 131 EUROPE IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%) 518
FIGURE 132 EUROPE ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%) 520
FIGURE 133 EUROPE ONCOLOGY MARKET SHARE, BY CANCER CARE,
(2021 V/S 2028) (%) 522
FIGURE 134 EUROPE INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION,
(2021 V/S 2028) (%) 524
FIGURE 135 EUROPE BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 526
FIGURE 136 EUROPE VIRAL INFECTION MARKET SHARE, BY INFECTION,
(2021 V/S 2028) (%) 528
FIGURE 137 EUROPE FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 530
FIGURE 138 EUROPE OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 532
FIGURE 139 EUROPE IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%) 534
FIGURE 140 EUROPE IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%) 536
FIGURE 141 EUROPE IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%) 538
FIGURE 142 GERMANY IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 541
FIGURE 143 GERMANY IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 542
FIGURE 144 GERMANY IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 543
FIGURE 145 U.K. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 545
FIGURE 146 U.K. IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 546
FIGURE 147 U.K. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 547
FIGURE 148 FRANCE IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 549
FIGURE 149 FRANCE IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 550
FIGURE 150 FRANCE IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 551
FIGURE 151 REST OF E.U. IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 554
FIGURE 152 REST OF E.U. IVD MARKET REVENUE, BY APPLICATION
(2021 V/S 2028) ($MN) 555
FIGURE 153 REST OF E.U. IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 556
FIGURE 154 APAC IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%) 560
FIGURE 155 APAC IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%) 562
FIGURE 156 APAC IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 564
FIGURE 157 APAC CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 566
FIGURE 158 APAC MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 568
FIGURE 159 APAC IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%) 570
FIGURE 160 APAC ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%) 572
FIGURE 161 APAC ONCOLOGY MARKET SHARE, BY CANCER CARE, (2021 V/S 2028) (%) 574
FIGURE 162 APAC INFECTIOUS DISEASES MARKET SHARE BY APPLICATION,
(2021 V/S 2028) (%) 576
FIGURE 163 APAC BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 578
FIGURE 164 APAC VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 580
FIGURE 165 APAC FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 582
FIGURE 166 APAC OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 584
FIGURE 167 APAC IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%) 586
FIGURE 168 APAC IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%) 588
FIGURE 169 APAC IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%) 590
FIGURE 170 JAPAN IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 592
FIGURE 171 JAPAN IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 593
FIGURE 172 JAPAN IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 594
FIGURE 173 CHINA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 597
FIGURE 174 CHINA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 598
FIGURE 175 CHINA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 599
FIGURE 176 INDIA IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 602
FIGURE 177 INDIA IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 603
FIGURE 178 INDIA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 604
FIGURE 179 REST OF APAC IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 608
FIGURE 180 REST OF APAC IVD MARKET REVENUE, BY APPLICATION
(2021 V/S 2028) ($MN) 609
FIGURE 181 REST OF APAC IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 610
FIGURE 182 ROW IVD MARKET SHARE, BY PRODUCT, (2021 V/S 2028) (%) 614
FIGURE 183 ROW IVD MARKET SHARE, BY TECHNOLOGY, (2021 V/S 2028) (%) 616
FIGURE 184 ROW IMMUNOCHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 618
FIGURE 185 ROW CLINICAL CHEMISTRY MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 620
FIGURE 186 ROW MOLECULAR DIAGNOSTICS MARKET SHARE, BY TECHNIQUE,
(2021 V/S 2028) (%) 622
FIGURE 187 ROW IVD MARKET SHARE, BY APPLICATION, (2021 V/S 2028) (%) 624
FIGURE 188 ROW ONCOLOGY MARKET SHARE, BY CANCER TYPE, (2021) (%) 626
FIGURE 189 ROW CANCER DIAGNOSTICS MARKET REVENUE, BY CANCER CARE,
(2021 V/S 2028) (%) 628
FIGURE 190 ROW INFECTIOUS DISEASES MARKET SHARE, BY APPLICATION,
(2021 V/S 2028) (%) 630
FIGURE 191 ROW BACTERIAL INFECTION MARKET SHARE, BY TYPE OF INFECTION, (2021 V/S 2028) (%) 632
FIGURE 192 ROW VIRAL INFECTION MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 634
FIGURE 193 ROW FUNGAL INFECTION MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 636
FIGURE 194 ROW OTHER INFECTIONS MARKET SHARE, BY TYPE OF INFECTION,
(2021 V/S 2028) (%) 638
FIGURE 195 ROW IVD MARKET SHARE, BY SAMPLE SOURCE, (2021 V/S 2028) (%) 640
FIGURE 196 ROW IVD MARKET SHARE, BY END-USERS, (2021 V/S 2028) (%) 642
FIGURE 197 ROW IVD MARKET SHARE, BY COUNTRY, (2021 V/S 2028) (%) 644
FIGURE 198 BRAZIL IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY,
(2021 V/S 2028) ($MN) 647
FIGURE 199 BRAZIL IVD MARKET REVENUE, BY APPLICATION (2021 V/S 2028) ($MN) 648
FIGURE 200 BRAZIL IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER,
(2021 V/S 2028) ($MN) 649
FIGURE 201 REST OF LATAM IVD MARKET REVENUE, BY PRODUCT AND BY TECHNOLOGY, (2021 V/S 2028) ($MN) 651
FIGURE 202 REST OF LATAM IVD MARKET REVENUE, BY APPLICATION
(2021 V/S 2028) ($MN) 652
FIGURE 203 REST OF LATIN AMERICA IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 653
FIGURE 204 MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY PRODUCT AND
BY TECHNOLOGY, (2021 V/S 2028) ($MN) 656
FIGURE 205 MIDDLE EAST & OTHERS MARKET REVENUE, BY APPLICATION
(2021 V/S 2028) ($MN) 657
FIGURE 206 MIDDLE EAST & OTHERS IVD MARKET REVENUE, BY SAMPLE SOURCE AND END-USER, (2021 V/S 2028) ($MN) 658
FIGURE 207 KEY GROWTH STRATEGIES (2020-2021) 659
FIGURE 208 SWOT: ABBOTT LABORATORIES 693
FIGURE 209 SWOT: BIOMEREIEUX 705
FIGURE 210 SWOT: DANAHER CORPORATION 727
FIGURE 211 SWOT: DEXCOM INC. 734
FIGURE 212 SWOT: F. HOFFMANN LA ROCHE 747
FIGURE 213 SWOT: HOLOGIC, INC. 756
FIGURE 214 SWOT: QUIDEL CORPORATION 765
FIGURE 215 SWOT: SIEMENS HEALTHINEERS 776
FIGURE 216 SWOT: SYSMEX 782
FIGURE 217 SWOT: THERMO FISHER SCIENTIFIC 792

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+